1 2	State of Arkansas As Engrossed: $84/15/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$ $14/21/21$
3	Regular Session, 2021 SENATE BILL 639
4	Tregular Session, 2021
5	By: Senator K. Hammer
6	By: Representative Cloud
7	
8	For An Act To Be Entitled
9	AN ACT TO AUTHORIZE OFF-LABEL USE OF DRUG TREATMENTS
10	TO TREAT PATIENTS DIAGNOSED WITH PEDIATRIC ACUTE-
11	ONSET NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC
12	AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH
13	STREPTOCOCCAL INFECTION; AND FOR OTHER PURPOSES.
14	
15	
16	Subtitle
17	TO AUTHORIZE OFF-LABEL USE OF DRUG
18	TREATMENTS TO TREAT PATIENTS DIAGNOSED
19	WITH PEDIATRIC ACUTE-ONSET
20	NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC
21	AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS
22	ASSOCIATED WITH STREPTOCOCCAL INFECTION.
23	
24	
25	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
26	
27	SECTION 1. Arkansas Code Title 23, Chapter 79, Subchapter 19, is
28	amended to add an additional section to read as follows:
29	23-79-1903. Off-label use of drug treatment to treat pediatric acute-
30	onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric
31 32	disorders associated with streptococcal infection - Legislative findings -
33	Definitions. (a) The General Assembly finds that:
34	(1) Pediatric acute-onset neuropsychiatric syndrome, also known
35	as "PANS", is a clinically defined disorder characterized by the sudden onset
36	of obsessive-compulsive symptoms or eating restrictions, accompanied by two

1	(2) or more symptoms of acute behavioral deterioration or motor and sensory
2	changes, or both;
3	(2) Pediatric autoimmune neuropsychiatric disorders associated
4	with streptococcal infection, also known as "PANDAS", is a term used to
5	describe a subset of symptoms affecting children and adolescents within the
6	broader PANS classification;
7	(3) Other states may require coverage for off-label use of drug
8	treatments to treat pediatric acute-onset neuropsychiatric syndrome and
9	pediatric autoimmune neuropsychiatric disorders associated with streptococcal
10	infection; and
11	(4) Arkansas does not require coverage for off-label use of drug
12	treatments to treat patients who are diagnosed with pediatric acute-onset
13	neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders
14	associated with streptococcal infections.
15	(b) As used in this section:
16	(1)(A) "Health benefit plan" means an individual, blanket, or
17	any group plan, policy, or contract for healthcare services issued, renewed,
18	or extended in this state by a healthcare insurer, health maintenance
19	organization, hospital medical service corporation, or self-insured
20	governmental or church plan in this state.
21	(B) "Health benefit plan" includes:
22	(i) A plan offered by a risk-based provider
23	organization as established under the Medicaid Provider-Led Organized Care
24	Act, § 20-77-2701 et seq.;
25	(ii) Indemnity and managed care plans; and
26	(iii) Plans providing health benefits to state and
27	public school employees under § 21-5-401 et seq.
28	(C) "Health benefit plan" does not include:
29	(i) A plan that provides only dental benefits or eye
30	and vision care benefits;
31	(ii) A disability income plan;
32	(iii) A credit insurance plan;
33	(iv) Insurance coverage issued as a supplement to
34	liability insurance;
35	(v) Medical payments under an automobile or
36	homeowners' insurance plan;

1	(vi) A health benefit plan provided under Arkansas
2	Constitution, Article 5, § 32, the Workers' Compensation Law, § 11-9-101 et
3	seq., and the Public Employee Workers' Compensation Act, § 21-5-601 et seq.;
4	(vii) A plan that provides only indemnity for
5	hospital confinement;
6	(viii) An accident-only plan; or
7	(ix) A specified disease plan; and
8	(2)(A) "Healthcare insurer" means any insurance company,
9	hospital and medical service corporation, or health maintenance organization
10	that issues or delivers health benefit plans in this state and is subject to
11	any of the following laws:
12	(i) The insurance laws of this state;
13	(ii) Section 23-75-101 et seq., pertaining to
14	hospital and medical service corporations;
15	(iii) Section 23-76-101 et seq., pertaining to
16	health maintenance organizations; or
17	(iv) A risk-based provider organization established
18	under the Medicaid Provider-Led Organized Care Act, § 20-77-2701 et seq.
19	(B) "Healthcare insurer" does not include an entity that
20	provides only dental benefits or eye and vision care benefits.
21	(c) A health benefit plan that is offered, issued, or renewed in this
22	state, including a plan offered by a risk-based provider organization
23	established under the Medicaid Provider-Led Organized Care Act, § 20-77-2701
24	et seq., shall provide coverage for off-label use of intravenous
25	immunoglobulin, also known as "IVIG", to treat individuals diagnosed with
26	pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune
27	neuropsychiatric disorders associated with streptococcal infection, or both,
28	on or after January 1, 2022, under a patient-specific treatment plan
29	$\underline{established} \ \ \underline{by} \ \ \underline{the} \ \ \underline{Childhood} \ \ \underline{Post-infectious} \ \ \underline{Autoimmune} \ \ \underline{Encephalopathy} \ \ \underline{Clinic}$
30	established by the University of Arkansas for Medical Sciences in
31	collaboration with Arkansas Children's Hospital.
32	(d) The coverage for off-label use of drug treatment to treat
33	pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune
34	$\underline{\text{neuropsychiatric disorders associated with streptococcal infection under } \underline{\text{this}}$
35	section:
36	(1) May be subject to policy deductions or copayment

2	insurer or a health benefit plan; and
3	(2) Does not diminish or limit benefits otherwise allowable
4	under a health benefit plan.
5	(e) The Insurance Commissioner shall develop and promulgate rules for
6	the implementation and administration of this section.
7	
8	/s/K. Hammer
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	

1 requirements and any standard prior authorization review of a healthcare